 |
|
Drug used for advanced cancer could cause exposed bone in jaw
October 03, 2006Condition affects up to 10 percent of advanced cancer patients, U-M researchers report
ANN ARBOR, Mich. - A type of drug used to strengthen bones when cancer has spread there may be linked to a side effect that involves deterioration of the jaw bone, according to two new reviews of cancer literature. The condition, called osteonecrosis of the jaw, is marked by exposed bone in the jaw and can lead to infection, inflammation and pain.
While researchers do not fully understand the condition or what causes it, osteonecrosis of the jaw, or ONJ, appears to occur in individuals who have been treated with drugs called bisphosphonates, which are used to improve bone strength. When treating bone affected by cancer, the bisphosphonates are given intravenously and have been shown to decrease the risk of skeletal complications such as fracture.
"Osteonecrosis of the jaw is not a common condition. It appears to occur in 1 percent to 10 percent of patients with advanced cancer who are on intravenous bisphosphonate therapy - a number significant enough that most medical oncologists will see patients with this condition. It is important that researchers learn why it occurs and how best to prevent or treat it," says Catherine Van Poznak, M.D., assistant professor of internal medicine at the University of Michigan Medical School.
Van Poznak has authored two recent reviews of osteonecrosis of the jaw. One study appears in the October issue of Current Opinions in Orthopaedics. The other was published in August in the journal Oncology. Both papers synthesize the present data for an overview of what is known to date about this recently identified complication.
ONJ is marked by exposed, non-healing bone. Pain, swelling and inflammation are the most common symptoms but the lesions can have no symptoms. ONJ typically develops months or years after therapy with intravenous bisphosphonates begins. Researchers have noted that when ONJ occurs, it usually follows an invasive dental procedure such as an extraction where the wound does not heal in a normal fashion. To try to prevent ONJ, it has been suggested that patients maximize their oral health and take care of any invasive dental work before they begin bisphosphonate therapy.
"No reported treatment has proven successful for osteonecrosis of the jaw, which means for now the focus is on prevention or alleviating symptoms once it develops. We do not know how to predict who will develop ONJ or who is most at risk," says Van Poznak, a breast oncologist at the U-M Comprehensive Cancer Center who treats patients whose cancer has metastasized to bone.
"Some patients have resolution of the lesion but in other patients, it may remain stable or even progress," Van Poznak adds.
Patients with osteoporosis also take bisphosphonates, although their treatment is typically prescribed as a pill, rather than intravenously. Some cases of ONJ have been reported in patients with osteoporosis who are taking oral bisphosphonates, but the risk of ONJ to such patients appears to be very low.
Previous studies have noted anywhere from 0.6 percent to 10 percent of patients with cancer on bisphosphonates developed ONJ. Reporting is currently voluntary. The problem, Van Poznak says, is that the condition itself is poorly defined and no universal reporting mechanism exists.
To address these challenges, clinical trials are being designed to help better define the condition. These upcoming clinical trials investigating bisphosphonate therapy for advanced cancer will include monitoring for ONJ, and researchers hope to learn what causes the condition to develop.
University of Michigan Health System
"Osteonecrosis of the jaw is not a common condition. It appears to occur in 1 percent to 10 percent of patients with advanced cancer who are on intravenous bisphosphonate therapy - a number significant enough that most medical oncologists will see patients with this condition. It is important that researchers learn why it occurs and how best to prevent or treat it," says Catherine Van Poznak, M.D., assistant professor of internal medicine at the University of Michigan Medical School.
Van Poznak has authored two recent reviews of osteonecrosis of the jaw. One study appears in the October issue of Current Opinions in Orthopaedics. The other was published in August in the journal Oncology. Both papers synthesize the present data for an overview of what is known to date about this recently identified complication.
ONJ is marked by exposed, non-healing bone. Pain, swelling and inflammation are the most common symptoms but the lesions can have no symptoms. ONJ typically develops months or years after therapy with intravenous bisphosphonates begins. Researchers have noted that when ONJ occurs, it usually follows an invasive dental procedure such as an extraction where the wound does not heal in a normal fashion. To try to prevent ONJ, it has been suggested that patients maximize their oral health and take care of any invasive dental work before they begin bisphosphonate therapy.
"No reported treatment has proven successful for osteonecrosis of the jaw, which means for now the focus is on prevention or alleviating symptoms once it develops. We do not know how to predict who will develop ONJ or who is most at risk," says Van Poznak, a breast oncologist at the U-M Comprehensive Cancer Center who treats patients whose cancer has metastasized to bone.
"Some patients have resolution of the lesion but in other patients, it may remain stable or even progress," Van Poznak adds.
Patients with osteoporosis also take bisphosphonates, although their treatment is typically prescribed as a pill, rather than intravenously. Some cases of ONJ have been reported in patients with osteoporosis who are taking oral bisphosphonates, but the risk of ONJ to such patients appears to be very low.
Previous studies have noted anywhere from 0.6 percent to 10 percent of patients with cancer on bisphosphonates developed ONJ. Reporting is currently voluntary. The problem, Van Poznak says, is that the condition itself is poorly defined and no universal reporting mechanism exists.
To address these challenges, clinical trials are being designed to help better define the condition. These upcoming clinical trials investigating bisphosphonate therapy for advanced cancer will include monitoring for ONJ, and researchers hope to learn what causes the condition to develop.
University of Michigan Health System
Advanced Cancer Current Events and Advanced Cancer News RSSCommon pain relief medication may encourage cancer growth
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.
Drugs to treat anemia in cancer patients linked to thromboembolism
Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center.
New data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas
Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.
New drug aims to 'seek and destroy' many types of cancer
A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
Palliative care intervention for patients with advanced cancer provides quality of life benefits
Patients with advanced cancer who received a palliative care intervention focused on addressing physical and psychosocial issues and care coordination that was provided at the same time as cancer treatment reported improved quality of life and mood but did not experience a significant change in the number of days in the hospital or the severity of their symptoms compared to patients who received usual care.
Smoking increases potential for metastatic pancreatic cancer
Smoking has once again been implicated in the development of advanced cancer. Exposure to nicotine by way of cigarette smoking may increase the likelihood that pancreatic ductal adenocarcinoma will become metastatic.
NIST discovers how strain at grain boundaries suppresses high-temperature superconductivity
Researchers at the National Institute of Standards and Technology (NIST) have discovered that a reduction in mechanical strain at the boundaries of crystal grains can significantly improve the performance of high-temperature superconductors (HTS).
Stem cell protein offers a new cancer target
A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.
Focus on treating malnutrition in cancer patients, researchers say
Cancer patients who are malnourished experience significantly greater levels of psychological distress than those who are more adequately nourished, according to new results reported at the European Society for Medical Oncology's Symposium on Cancer and Nutrition (Zurich, 20-21 March 2009).
Research shows biopsy of recurrent breast cancer can alter treatment
For women with recurrent breast cancer, the treatment the doctor chooses is usually based on the properties of their original breast cancer. A group from Toronto has recently completed the world's first study that compared original breast cancer tumors with a biopsy of suspected tumors that recurred elsewhere in the body.
More Advanced Cancer Current Events and Advanced Cancer News Articles
 |
A Cancer Therapy: Results of Fifty Cases and the Cure of Advanced Cancer by Max Gerson (Author) |
|
The Quiet War: Profiles of Women Facing Advanced Breast Cancer/Resource Guide Starring: Documentary Directed By: Mary Katzke The Quiet War was created to be a source of information and an extensive resource for women facing Advanced Breast Cancer, i.e. cancer that has spread beyond the breast. The film was also created to increase awareness and sensitivity for these women by their caregivers and medical professionals. The content of this film was shaped by cancer survivors and has been reviewed by medical professionals. It is meant to be a guide for women, not an exclusive resource. In the main film, you will meet: Stefanie, of Los Angeles California, who is 31 years old and has started a foundation to focus on awareness of breast cancer in younger women; Lynnly, a 52 year-old artist and photographer from San Francisco who gives eloquent voice to the practical aspects of living with this disease; ... | |
 |
BronchoPhase by Tango Advanced Nutrition BronchoPhase Lung Support Formula was developed by Dr. Jake Fratkin to support lung health, soothe inflamed tissues, and resolve chest discomfort and persistent cough. BronchoPhase provides herbs shown to shorten the length of a viral attack, resolve inflammation of bronchial tissues to relieve chest discomfort and persistent cough, and aid in expelling phlegm. |
 |
Advanced Colon Cancer Directed By: (c) Information Television Network |
 |
Romantic Camisole Pocket Bra by Mystique Intimates (Classique) Your breast forms look completely realistic inside the hidden inner pockets of this lace camisole pocket bra. Wider straps provide comfort & support of even the largest breast forms; lace detail provides an elegant look. Made by Classique/Monique |
 |
Frederic Fekkai Advanced Brilliant Glossing Cream 4 fl oz (113 g) by Frederic Fekkai & Co. Who is it for? Women with normal to dry, dull hair, who seek moisture and radiant, reflective shine. Frizz-fighting, soft-seeking shine cream works for nearly every hair type. With encapsulated olive oil spheres to instantly reboot shine all day long. Our superstar formula, ever so brilliant. Advanced Technology - Encapsulated Shine-Release Complex Key Ingredient: Olive Oil Brilliant Glossing takes inspiration from nature with its winning olive oil formula, and incorporates new encapsulation technology in Fekkai Advanced. Micro-encapsulation technology allows finer olive oil droplets to target and cover your hair for even distribution & coverage from the root to the tip. With our encapsulated Shine-Release Complex, Brilliant Glossing formulas will deliver refreshed shine... |
 |
Xango Juice-Mangosteen Juice Drink, 4 Bottles by Xango A delicious dietary supplement, XanGoTM Juice harnesses the nutritional power of the whole mangosteen fruit through a potent proprietary formula. Just one to three ounces each day unleashes a concentrated rush of xanthonesa vigorous family of phytonutrients. The best part: sensational flavor thatll keep you coming back for more and more. XanGo ensures exceptional product quality standards from the mangosteen tree to the bottle of XanGoTM Juice. Each bottle meets strict ISO standards and passes hundreds of quality tests before the premium dietary supplement is served to consumers worldwide. XanGo Juice boasts a proprietary wholefruit formula, harnessing a concentrated rush of xanthonesa vigorous family of nextgeneration phytonutrients. Sounds complex. But heres the straight scoop.... |
 |
The Secret Of Creating Your Future: Simple Yet Powerful Concepts For Bringing Your Dreams Into Reality, Now! By Tad James, M.S., PH.D. Published by Advanced Neuro Dynamics, Inc. (Softcover, 128 Pages, 1989 Version) by Published by Advanced Neuro Dynamics Creating Your Future assists one in designing a life exactly that one wants. If you "create" your future and understand what it takes to get the life you want, you're more likely to achieve that goal. This book is very easy to read, altho it does contain exercises that require thinking & writing down exactly waht you want but once you do it you're guaranteed to be astounded at the results you will achieve. |
 |
The Cure For All Advanced Cancers by Hulda Regehr Clark (Author) Cancer can now be cured, not only the early stages, but also advanced cancer, stages four and five, including imminent death. We are not accustomed to thinking about a cure. We think of remission as the only possiblity. But this book is not about remission. It is about a cure. this is possible because the true cause of cancer has been found. The Cause of the malignancy is explained in the earlier book, The Cure For All Cancers. But removing the malignancy left behind the tumors as they were, prior to the malignant development. So, eliminating tumors became the focus of additional research, and is the subject of this book. The 21 Day Program described in this book does both. Once you win this battle, even advanced cancer can be cured. The success rate for advanced cancer is about... |
 |
Thyroid Disease: What's New in Diagnosis and Management?/Combined Modality Approaches to Locally Advanced Non-Small-Cell Lung Cancer (NCME Video 686) Also With: Network For Continuing Medical Education (Primary Contributor), H. Jack Baskin (Primary Contributor), Robert B. Livinston (Primary Contributor) pt. 1. Screening -- pt. 2. Patient evaluation -- pt. 3. Additional tests & management of hypo- and hyperthyroidism -- pt. 4. Structural abnormalities and thyroid cancer. |
| © 2009 BrightSurf.com |